Viewing Study NCT05104866


Ignite Creation Date: 2025-12-24 @ 4:30 PM
Ignite Modification Date: 2025-12-26 @ 8:33 AM
Study NCT ID: NCT05104866
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-04-14
First Post: 2021-10-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Sponsor: AstraZeneca
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module